Dyax received a CRL for its drug to treat hereditary angioedema on March 25, 2009.

FORBES: How Long Will It Take For Arena's Obesity Drug To Be Approved?

However, the gains in CRL and HUN appear more reflective of their strong quarterly earnings performances than any traction preserved from their initial buyout chatter.

FORBES: Life for Sale

No biotech executive wants to be the first to make a CRL public, and certainly no executive wants to be the only one to lift this particular kimono.

FORBES: MannKind Becomes Poster Child For Dangers Of FDA Secrecy

Others, like Eric Halperin, a director at the CRL, don't.

FORBES: Don't Get Fleeced By Overdraft Fees

Back in January, shares of Charles River Laboratories (CRL), another Forbes Investor recommendation, jumped 17.3% after similar rumors that it was pursuing a sale to private equity firms was reported by dealReporter, a provider of relevant market moving news.

FORBES: The Power of Private Equity Speculation